PURPOSE: Florbetaben is a β-amyloid-targeted PET tracer with significant potential for augmenting the toolbox in the clinical diagnosis of Alzheimer's disease (AD). In dementia imaging, shortening of scan duration may simplify future clinical use. The aim of this retrospective study was to investigate the effect of scan duration on diagnostic accuracy. METHODS: PET scans obtained from 25 AD patients and 25 healthy volunteers (HVs) were analysed. In each subject, scans of three different durations (5, 10 and 20 min; all starting 90 min after injection) were obtained, randomized, and visually assessed by three experts blinded to the subject's identity and group affiliation. Presence/absence of β-amyloid and diagnostic confidence (0-100 %) were scored, and 10 % of the scans were re-read. Further, randomly selected datasets of ten AD patients and ten HVs were quantified using an established VOI-based approach and using a voxel-based approach. RESULTS: The sensitivity and specificity of the blinded read were 80 % and 96 %, respectively, for all scan durations. Diagnostic confidence was high (97 ± 6 %, 97 ± 6 % and 95 ± 8 % for the 20-min, 10-min and 5-min scans, respectively; n.s.), as was interreader agreement (kappa(20 min) = 0.94, kappa(10 min) = 0.94, kappa(5 min) = 0.89; n.s.). Intrareader agreement was highest for the 20-min scan (kappa = 1.00) and lower for the 10-min scan (kappa = 0.71) and 5-min scan (kappa = 0.80; p = 0.002 and 0.003 vs. the 20-min scan). For all scan durations, composite SUVRs (Cohen's d effect size 4.5, 3.9 and 4.8 for the 5-min, 10-min and 20-min scans; p < 0.0001 each) and individual brain volumes affected by β-amyloid (Cohen's d effect size 1.6, 1.8 and 2.0 for the 5-min, 10-min and 20-min scans; p < 0.005 each) were significantly higher in AD patients than in HVs. CONCLUSION: Reduction in scan duration did not relevantly affect the accuracy of florbetaben PET scans in discriminating between AD patients and HVs. Thus, a reduction in scan duration seems conceivable for the future clinical use of florbetaben.
PURPOSE:Florbetaben is a β-amyloid-targeted PET tracer with significant potential for augmenting the toolbox in the clinical diagnosis of Alzheimer's disease (AD). In dementia imaging, shortening of scan duration may simplify future clinical use. The aim of this retrospective study was to investigate the effect of scan duration on diagnostic accuracy. METHODS: PET scans obtained from 25 ADpatients and 25 healthy volunteers (HVs) were analysed. In each subject, scans of three different durations (5, 10 and 20 min; all starting 90 min after injection) were obtained, randomized, and visually assessed by three experts blinded to the subject's identity and group affiliation. Presence/absence of β-amyloid and diagnostic confidence (0-100 %) were scored, and 10 % of the scans were re-read. Further, randomly selected datasets of ten ADpatients and ten HVs were quantified using an established VOI-based approach and using a voxel-based approach. RESULTS: The sensitivity and specificity of the blinded read were 80 % and 96 %, respectively, for all scan durations. Diagnostic confidence was high (97 ± 6 %, 97 ± 6 % and 95 ± 8 % for the 20-min, 10-min and 5-min scans, respectively; n.s.), as was interreader agreement (kappa(20 min) = 0.94, kappa(10 min) = 0.94, kappa(5 min) = 0.89; n.s.). Intrareader agreement was highest for the 20-min scan (kappa = 1.00) and lower for the 10-min scan (kappa = 0.71) and 5-min scan (kappa = 0.80; p = 0.002 and 0.003 vs. the 20-min scan). For all scan durations, composite SUVRs (Cohen's d effect size 4.5, 3.9 and 4.8 for the 5-min, 10-min and 20-min scans; p < 0.0001 each) and individual brain volumes affected by β-amyloid (Cohen's d effect size 1.6, 1.8 and 2.0 for the 5-min, 10-min and 20-min scans; p < 0.005 each) were significantly higher in ADpatients than in HVs. CONCLUSION: Reduction in scan duration did not relevantly affect the accuracy of florbetaben PET scans in discriminating between ADpatients and HVs. Thus, a reduction in scan duration seems conceivable for the future clinical use of florbetaben.
Authors: N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot Journal: Neuroimage Date: 2002-01 Impact factor: 6.556
Authors: John Lister-James; Michael J Pontecorvo; Chris Clark; Abhinay D Joshi; Mark A Mintun; Wei Zhang; Nathaniel Lim; Zhiping Zhuang; Geoff Golding; Seok Rye Choi; Tyler E Benedum; Paul Kennedy; Franz Hefti; Alan P Carpenter; Hank F Kung; Daniel M Skovronsky Journal: Semin Nucl Med Date: 2011-07 Impact factor: 4.446
Authors: Timo Suotunen; Jussi Hirvonen; Pirjo Immonen-Räihä; Sargo Aalto; Irina Lisinen; Eveliina Arponen; Mika Teräs; Kari Koski; Raimo Sulkava; Marko Seppänen; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2010-02-09 Impact factor: 9.236
Authors: Henryk Barthel; Julia Luthardt; Georg Becker; Marianne Patt; Eva Hammerstein; Kristin Hartwig; Birk Eggers; Bernhard Sattler; Andreas Schildan; Swen Hesse; Philipp M Meyer; Henrike Wolf; Torsten Zimmermann; Joachim Reischl; Beate Rohde; Hermann-Josef Gertz; Cornelia Reininger; Osama Sabri Journal: Eur J Nucl Med Mol Imaging Date: 2011-05-06 Impact factor: 9.236
Authors: Kevin T Chen; Matti Schürer; Jiahong Ouyang; Mary Ellen I Koran; Guido Davidzon; Elizabeth Mormino; Solveig Tiepolt; Karl-Titus Hoffmann; Osama Sabri; Greg Zaharchuk; Henryk Barthel Journal: Eur J Nucl Med Mol Imaging Date: 2020-06-13 Impact factor: 9.236
Authors: Kevin T Chen; Tyler N Toueg; Mary Ellen Irene Koran; Guido Davidzon; Michael Zeineh; Dawn Holley; Harsh Gandhi; Kim Halbert; Athanasia Boumis; Gabriel Kennedy; Elizabeth Mormino; Mehdi Khalighi; Greg Zaharchuk Journal: Eur J Nucl Med Mol Imaging Date: 2021-01-08 Impact factor: 9.236
Authors: Miguel A Chávez-Fumagalli; Pallavi Shrivastava; Jorge A Aguilar-Pineda; Rita Nieto-Montesinos; Gonzalo Davila Del-Carpio; Antero Peralta-Mestas; Claudia Caracela-Zeballos; Guillermo Valdez-Lazo; Victor Fernandez-Macedo; Alejandro Pino-Figueroa; Karin J Vera-Lopez; Christian L Lino Cardenas Journal: J Alzheimers Dis Rep Date: 2021-01-11